Official media partner of business and marketing eventsEvents calendar
VANTAGE52

Loading market data

Entrepreneurs

Isomorphic Labs Raises $5 Billion Before Its First Drug Reaches a Clinical Trial

Greenoaks and Sequoia co-led the Series C announced on 17 November, with Alphabet investing again. Isomorphic gave no valuation, though Bloomberg reported talks at about $50 billion. Its drug candidates are still preclinical.

Night collage of a drug discovery laboratory with robotic pipetting stations under blue light, a protein structure on a wall screen and the Isomorphic Labs logo on a glass door
Illustration by VANTAGE52
VANTAGE52 Editorial · Edited by VANTAGE52 Editorial

Isomorphic Labs, the London drug-discovery company formed out of Alphabet’s DeepMind in 2021, announced a $5 billion Series C on 17 November. Greenoaks and Sequoia Capital co-led the round, Andreessen Horowitz joined among several new investors, and Alphabet made what the company called a continued significant investment.

Isomorphic did not disclose a valuation. Bloomberg reported on 5 November, citing people familiar with the matter, that the round was being negotiated at a valuation of about $50 billion and that details could still change. The company has not confirmed that figure.

The raise is Isomorphic’s third outside round in less than 20 months and by far its largest, yet none of its drug candidates has entered a clinical trial. The company says positive preclinical results in oncology and immunology “set the stage for clinical entry”. Demis Hassabis, its founder and chief executive, said in January that it expected to begin its first trials by the end of 2026, Bloomberg reported.

Who Wrote the Cheques

The investor list shows how Alphabet now funds the business. GV and CapitalG, its venture and growth investment arms, invested again. So did Thrive Capital, which led both earlier rounds, along with MGX, Temasek and the UK Sovereign AI Fund. Greenoaks and Sequoia, which were not among the existing investors the company named, led this time.

Sequoia’s part stands out for its timing. The firm announced about $10 billion of new funds on 4 November and said it would close its London office and invest more selectively. Within two weeks it co-led a round for a company headquartered in London. The UK Sovereign AI Fund, which also backed the chip designer Fractile in a round of more than £500 million, took part again as an existing investor.

For Alphabet, outside leads do two jobs. They give the business a price set by investors other than its parent, and they share the cost of the next stage, which Isomorphic says includes building its own clinical development capability.

From $600 Million to $5 Billion in 20 Months

Isomorphic’s first outside money arrived on 31 March 2025, $600 million led by Thrive, with GV taking part and Alphabet adding follow-on capital. In May 2026 it raised $2.1 billion in a Series B, again led by Thrive, with Alphabet, Temasek, CapitalG and the UK Sovereign AI Fund participating. With the Series C, the three rounds total $7.7 billion.

The size is unusual for biotechnology. When the Series B was announced, BioSpace reported that analysts called it the second largest biotech round on record, behind the roughly $3 billion Altos Labs raised when it emerged in 2022. The Series C is larger than either.

What the Money Is Meant to Build

Isomorphic lists four uses. It wants to mature IsoDDE, its drug design engine, expand into new areas of biology, build an ecosystem of partners, and create what it calls AI-first translational and clinical development infrastructure.

The last item marks the change. Until now Isomorphic has worked on discovery, the stage before a medicine is tested in people, through its own programmes and through research deals with drugmakers. Building translational and clinical capacity means preparing to run that testing itself. Those costs are large even for the biggest companies in the industry. Pfizer, for one, has agreed that funds managed by Blackstone will cover up to $1.5 billion of development costs for a single obesity drug.

Isomorphic’s leaders have also set a clock. Hassabis’s January target of first trials by the end of 2026 now has about six weeks left to run. Max Jaderberg, the company’s president, described the work as still preclinical and the company as in the “first innings” at Bloomberg’s technology conference in London, Bloomberg reported. The Series C announcement gives no trial date.

Partners Pay Millions While Investors Pay Billions

The commercial record is smaller, at least in the cash the company has disclosed. On 7 January 2024 Isomorphic announced research collaborations with Eli Lilly and Novartis that carried upfront payments of $45 million and $37.5 million. It said the two deals could be worth nearly $3 billion with milestones, before any royalties on future sales.

More partners have followed. On 19 November, two days after the Series C, Isomorphic announced a strategic research collaboration with MSD, without disclosing financial terms. Its partnerships page also lists Johnson & Johnson and an expanded Novartis collaboration, again without figures.

Set against $7.7 billion of equity, the $82.5 million of disclosed upfront payments shows where the value is expected to come from. Milestones and royalties are earned only as molecules advance through trials and reach the market. Taking its own candidates into the clinic would let Isomorphic keep more of that value, and would also leave it carrying more of the cost and the risk of failure.

The Test a Reported $50 Billion Price Sets

If Bloomberg’s figure is close to the final price, the new money buys roughly a tenth of the company, on the strength of a design engine and a pipeline that has not yet reached patients. Neil Mehta, founder and managing partner of Greenoaks, described the case in the announcement, calling the discovery and development of new medicines “an optimization challenge of almost infinite scale”.

That case can only be proved in trials, and others are pursuing the same idea. Bloomberg noted that OpenAI released a life sciences research model this year. SiliconANGLE reported that several drugmakers already use IsoDDE, though none has been named, and Isomorphic says the engine produces better results than the physics-based methods the industry uses today. That is the company’s claim, and no independent comparison has been published.

The nearest dated test is the one Isomorphic set itself. A first trial started before 31 December would meet the target Hassabis gave in January. Which disease it addresses, and whether the molecule is wholly owned or partnered, will show how much of the $5 billion is going into a pipeline Isomorphic intends to keep.

Tags

Key Concepts

Share this story

Sources

Where the reporting above comes from. Follow these to check the figures and statements for yourself.

More From Business

Choose which cookies we may use. You can change this at any time from “Manage cookies” at the foot of every page.